Overview

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
Phase:
Phase 2
Details
Lead Sponsor:
Eiger BioPharmaceuticals
Treatments:
Interferon-alpha
Interferons
Lonafarnib
Peginterferon alfa-2a
Ritonavir